|
[1]
|
Committee opinion no 611: method for estimating due date[J]. Obstet Gynecol, 2014, 124: 863-866. |
|
[2]
|
Alfirevic Z, Keeney E, Dowswell T, et al. Labour induction with prostaglandins:a systematic review and network meta-analysis[J]. BMJ, 2015, 350:h217. doi: 10.1136/bmj.h217 |
|
[3]
|
Duley L, Dorling J, Gyte G. When should the umbilical cord be clamped?[J]. BMJ, 2015:h4206. doi: 10.1136/bmj.h4206 |
|
[4]
|
McDonald SJ, Middleton P, Dowswell T. et al. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes[J]. Cochrane Database Syst Rev, 2013, 7:CD004074. https://pubmed.ncbi.nlm.nih.gov/23843134/ |
|
[5]
|
Committee Opinion No. 644:The Apgar Score[J]. Obstet Gynecol, 2015, 126:e52-e55. doi: 10.1097/AOG.0000000000001108 |
|
[6]
|
Iliodromiti S, Mackay DF, Smith GCS, et al. Apgar score and the risk of cause-specific infant mortality:a population-based cohort study[J]. Lancet, 2014, 384:1749-1755. doi: 10.1016/S0140-6736(14)61135-1 |
|
[7]
|
Mhyre JM, D'Oria R, Hameed AB, et al. The maternal early warning criteria:a proposal from the national partnership for maternal safety[J]. Obstet Gynecol, 2014, 124:782-786. doi: 10.1097/AOG.0000000000000480 |
|
[8]
|
Committee Opinion No. 638:First-trimester risk assessment for early-onset preeclampsia[J]. Obstet Gynecol, 2015, 126:e25-e27. doi: 10.1097/AOG.0000000000001049 |
|
[9]
|
Committee Opinion Summary No. 638:first-trimester risk assessment for early-onset preeclampsia[J]. Obstet Gynecol, 2015, 126:689. doi: 10.1097/01.AOG.0000471175.95314.42 |
|
[10]
|
Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-Ⅱ):an open-label, randomised controlled trial[J]. Lancet, 2015, 385:2492-2501. doi: 10.1016/S0140-6736(14)61998-X |
|
[11]
|
Balsells M, Garcia-Patterson A, Sola I, et al. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes:a systematic review and meta-analysis[J]. BMJ, 2015, 350:h102. doi: 10.1136/bmj.h102 |
|
[12]
|
Committee Opinion No. 640:Cell-free DNA screening for fetal aneuploidy[J]. Obstet Gynecol, 2015, 126:e31-e37. doi: 10.1097/AOG.0000000000001051 |
|
[13]
|
Committee Opinion Summary No. 640:cell-free DNA screening for fetal aneuploidy[J]. Obstet Gynecol, 2015, 126:691-692. doi: 10.1097/01.AOG.0000471171.86798.ac |
|
[14]
|
Society for Maternal-Fetal Medicine (SMFM) Publications Committee. #36:Prenatal aneuploidy screening using cell-free DNA[J]. Am J Obstet Gynecol, 2015, 212:711-716. doi: 10.1016/j.ajog.2015.03.043 |
|
[15]
|
Benachi A, Letourneau A, Kleinfinger P, et al. Cell-free DNA analysis in maternal plasma in cases of fetal abnormalities detected on ultrasound examination[J]. Obstet Gynecol, 2015, 125:1330-1337. doi: 10.1097/AOG.0000000000000874 |
|
[16]
|
Sovio U, White IR, Dacey A, et al. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study:a prospective cohort study[J]. Lancet, 2015, 386:2089-2097. doi: 10.1016/S0140-6736(15)00131-2 |
|
[17]
|
Norton ME, Chauhan SP, Dashe JS. Society for maternal-fetal medicine (SMFM) clinical guideline #7:nonimmune hydrops fetalis[J]. Am J Obstet Gynecol, 2015, 212:127-139. doi: 10.1016/j.ajog.2014.12.018 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
